2 news items
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
VIR
13 May 24
patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, the Company
- Prev
- 1
- Next